Personal Genome Diagnostics (PGDx) advances the frontiers of cancer medicine through innovative genomic technologies for oncology researchers, drug developers, clinicians and patients. The expert team at PGDx draws on a deep understanding of cancer biology, extensive experience in cancer genomics and clinical oncology, and the company's distinctive technologies. These novel technologies precisely identify and characterize unique genomic alterations in tumors. PGDx is working toward broad patient access to its genomic approaches, through both a CLIA-certified facility providing comprehensive genomic services, as well as a technology transfer solution enabling other molecular laboratories to easily internalize testing.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 10/29/15 | $21,400,000 | Series A |
Nanjing Kaiyuan Growth Capital Investments Windham Venture Partners | undisclosed |
| 01/04/18 | $75,000,000 | Series B |
Bristol-Myers Squibb Co-win Healthcare Fund Helsinn Investment Fund Inova Strategic Investments Maryland Venture Fund Windham Venture Partners | undisclosed |
